STOCK TITAN

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Organogenesis Holdings Inc. (ORGO) will report its Q4 and fiscal year 2023 financial results on February 29th, followed by a conference call to discuss the results and provide a corporate update.
Positive
  • None.
Negative
  • None.

CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.

Management will host a conference call at 5:00 p.m. Eastern Time on February 29th to discuss the results of the quarter and fiscal year, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.


Organogenesis Holdings Inc. will report its Q4 and fiscal year 2023 financial results after the market closes on Thursday, February 29th.

Organogenesis Holdings Inc. focuses on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.

The conference call to discuss the financial results will take place at 5:00 p.m. Eastern Time on February 29th.

The live webcast of the conference call can be accessed on the company's website at investors.organogenesis.com.
Organogenesis Holdings Inc

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Finance, Financial Conglomerates
US
Canton

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.